MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jvoice.2026.06.027

Медицинская библиотека · Journal of voice : official journal of the Voice Foundation · 2026

Impact of Anti-IL-5 Therapy (Mepolizumab) on Objective Acoustic Voice Parameters in Type 2 Chronic Rhinosinusitis With Nasal Polyps.

Yıldırım İlhami, Karaoğullarından Ayşe, Erkan Sanem Okşan, Çevirme Leyla, Özden Güzin

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Biological therapies targeting type 2 inflammation have become an important treatment option for chronic rhinosinusitis with nasal polyps (CRSwNP). While their effects on polyp size and symptom severity are well documented, their potential impact on voice quality remains unknown. This study aimed to evaluate the effect of anti-interleukin-5 therapy (mepolizumab) on objective acoustic voice parameters in patients with type 2 CRSwNP.

METHODS

Eighteen adult patients with type 2 CRSwNP who had previously undergone endoscopic sinus surgery and were scheduled to receive mepolizumab were included. A control group consisted of 18 patients not receiving biological therapy. Voice recordings were obtained 3 months after surgery (baseline) and 6 months after initiation of therapy. Sustained vowel /a/ phonations were analyzed using Praat software. Fundamental frequency (F0), jitter, shimmer, noise-to-harmonics ratio (NHR), and harmonics-to-noise ratio (HNR) were evaluated. Within- and between-group comparisons were performed using appropriate parametric and nonparametric tests, and effect sizes were calculated.

RESULTS

No significant baseline differences were observed between groups in any acoustic parameters. After 6 months, the mepolizumab group demonstrated significant reductions in jitter, shimmer, and NHR, and a significant increase in HNR compared with the control group with large to very large effect sizes. The most pronounced improvement was observed in NHR. Significant time*group interactions were detected for jitter, shimmer, NHR, and HNR (P < 0.001), indicating treatment-specific effects. Although F0 values changed significantly over time in both groups, no significant interaction effect was observed.

CONCLUSION

Mepolizumab has resulted in significant improvement in objective acoustic voice parameters in patients with type 2 chronic rhinosinusitis and nasal polyps. The greatest post-treatment change was observed in the NHR parameter.

Для цитирования: Yıldırım İlhami, Karaoğullarından Ayşe, Erkan Sanem Okşan, Çevirme Leyla, Özden Güzin. Impact of Anti-IL-5 Therapy (Mepolizumab) on Objective Acoustic Voice Parameters in Type 2 Chronic Rhinosinusitis With Nasal Polyps.. Journal of voice : official journal of the Voice Foundation. 2026. DOI: 10.1016/j.jvoice.2026.06.027.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.